What is Engitix?
Founded in 2016, Engitix operates at the intersection of advanced biotechnology and clinical research. The firm specializes in the discovery and development of drug targets derived from the human extracellular matrix, a critical component in the progression of fibrosis and solid tumors. By utilizing its proprietary platform, Engitix has successfully established a diverse portfolio of programs that address significant unmet medical needs. The company's strategic focus on ECM-based discovery allows for a more precise identification of therapeutic targets, effectively bridging the gap between laboratory research and clinical application. With its headquarters in London, Engitix maintains a competitive edge through high-value partnerships and a commitment to pioneering scientific methodologies in the oncology and fibrosis therapeutic spaces.
How much funding has Engitix raised?
Engitix has raised a total of $85.2M across 2 funding rounds:
Series A
$60.2M
Series A
$25M
Series A (2022): $60.2M with participation from Netherton Investments and Dompé farmaceutici S.P.A
Series A (2026): $25M, investors not publicly disclosed
Key Investors in Engitix
Netherton Investments
A private investment firm focused on long-term capital appreciation and strategic support for high-growth companies in the life sciences sector.
Dompé farmaceutici S.P.A
A global biopharmaceutical company with a strong emphasis on research and development, particularly in the areas of rare diseases and innovative therapeutic solutions.
Undisclosed Investor
An institutional investor participating in the latest funding round to support the continued development of the Engitix ECM platform.
What's next for Engitix?
With the recent infusion of capital, Engitix is well-positioned to accelerate its clinical development programs and deepen its research capabilities. The company is expected to prioritize the advancement of its existing pipeline, focusing on the transition of lead candidates toward clinical trials. Furthermore, the strategic nature of this financing suggests a continued emphasis on forming high-impact collaborations with global pharmaceutical entities to validate its ECM platform. As Engitix moves into this next phase of maturity, the focus will likely shift toward operational scaling and the commercialization of its proprietary discovery assets, ensuring that its innovative approach to drug target identification translates into tangible patient outcomes in the fields of oncology and chronic disease management.
See full Engitix company page
